Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.3000
0.00 (0.00%)
May 9, 2025, 1:25 PM - Market open
Adaptimmune Therapeutics Employees
Adaptimmune Therapeutics had 506 employees as of December 31, 2024. The number of employees increased by 57 or 12.69% compared to the previous year.
Employees
506
Change (1Y)
57
Growth (1Y)
12.69%
Revenue / Employee
$351,842
Profits / Employee
-$139,949
Market Cap
79.18M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ADAP News
- 2 days ago - Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 - Newsfile Corp
- 7 weeks ago - Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Adaptimmune Provides Q4 and Full Year 2024 Business Update - Newsfile Corp
- 2 months ago - Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025 - Newsfile Corp
- 3 months ago - Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Newsfile Corp
- 4 months ago - Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) - Newsfile Corp
- 5 months ago - Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK - Newsfile Corp
- 5 months ago - First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) - Newsfile Corp